Dr. Reddy’s Laboratories (NYSE:RDY) announces the launch of Avigan (Favipiravir) 200 mg tablets in India. The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co. Ltd.
Avigan has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild-to-moderate COVID-19 disease.
Dr. Reddy’s Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.